<?xml version="1.0" encoding="UTF-8"?>
<p>Interferon-deficient mice and the 
 <italic>Cynomolgus macaque</italic> CCHF animal models have allowed significant advancements in vaccine development.
 <sup>
  <xref rid="B75" ref-type="bibr">75â€“80</xref>
 </sup> The impact of type I and/or type II interferon deficiency on CCHF vaccine-induced adaptive immune responses, however, deserves further evaluation. The disease spectrum in the 
 <italic>Cynomolgus macaque</italic> depicts disease states seen in humans.
 <sup>
  <xref rid="B79" ref-type="bibr">79</xref>
 </sup> Despite issues around variability in observed disease outcomes,
 <sup>
  <xref rid="B81" ref-type="bibr">81</xref>
 </sup> the cost, and size of the animals, this immunocompetent animal model will be valuable in the development of CCHFV therapies. The addition of a humanized mouse model, which previously exhibited strain-specific virulence by producing different disease outcomes by a CCHFV Turkish and an Oman strain
 <sup>
  <xref rid="B78" ref-type="bibr">78</xref>
 </sup> would be a valuable addition to evaluate the interplay between pathogenicity and immunogenicity.
</p>
